news roundup
In this month’s updated list, companies include Adaptive Clinical Systems, Clinical SCORE, Crosstree, Signant Health, Raremark, Trialbee and more.
Charles River announced a multi-year discovery collaboration with Takeda to discover oncology, gastroenterology, neuroscience, and rare disease preclinical candidates that Takeda can advance into clinical development.
|
|
|
advertisement
AI in Action: Clinical Development AI Use Cases
Access an online resource with useful tools and practical information about advances in RBM. The site provides useful white papers, articles, webcasts, and more.
Access all resources
|
| |
|
CRO Novotech released its 'Asia-Pacific Industry Highlights 2019-2020' at JPM last week. As part of its briefing, it noted that clinical research in the APAC region has increased over 25% per year. This follows news from Australia that most clinical phase biotechs would be eligible for a 40%+ cash rebate on clinical research spend, preserved as an incentive for conducting clinical research in Australia.
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
| |
 |
|
|
|
Articles
In this Q&A, Jennifer Buell, PhD, chief operating officer at Agenus, a biotech focused on immuno-oncology, with a pipeline of checkpoint-modulating antibodies, cancer vaccines, adjuvants, and allogeneic adoptive cell therapies discusses the company's pipeline, and the direction of immuno-oncology as a whole.
Today, the industry is on the cusp of a revolution in the way toxicology studies are cataloged, analyzed, and leveraged, And it’s all because of a pilot project that was first launched by the FDA back in 2002 called the Standard for Exchange of Nonclinical Data (SEND) initiative.
|
|
|
advertisement
Three Key Critical Considerations Before Embarking on Decentralized Trials
Tuesday, January 28, 2020 at 11am EST | 8am PST | 4pm GMT | 5pm CET
Access all resources
|
| |
|
|
|
|
Blog Posts
In a commitment letter titled “New Biotechnology & Pharmaceutical Industry Commitment to Patients and the Public” a group of executives publicly pledged to back collaboration with healthcare entities, including payers, hospitals, and distributors, in efforts to eliminate co-pays and deductibles for all patients.
In this Q&A, Daniel de Boer, CEO at ProQR Therapeutics discusses how his company is advancing RNA therapies in retinal disorders.
| |
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
|
